What is Lifesci Capital’s Estimate for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Lifesci Capital issued their Q1 2026 earnings per share (EPS) estimates for Tenax Therapeutics in a report issued on Thursday, March 12th. Lifesci Capital analyst G. Maini forecasts that the specialty pharmaceutical company will post earnings per share of ($0.38) for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Tenax Therapeutics’ Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.54) EPS.

Other analysts have also recently issued research reports about the company. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday, March 10th. Cantor Fitzgerald initiated coverage on Tenax Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $35.00 price target on the stock. Guggenheim increased their price objective on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.67.

Tenax Therapeutics Stock Up 8.5%

Shares of Tenax Therapeutics stock opened at $15.17 on Monday. The company has a market capitalization of $94.66 million, a price-to-earnings ratio of -11.41 and a beta of 1.41. The stock’s 50-day simple moving average is $13.42 and its 200-day simple moving average is $10.13. Tenax Therapeutics has a 52 week low of $4.63 and a 52 week high of $18.38.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.88.

Hedge Funds Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TENX. Boothbay Fund Management LLC purchased a new position in Tenax Therapeutics during the third quarter worth about $2,680,000. Quadrature Capital Ltd purchased a new position in shares of Tenax Therapeutics in the fourth quarter valued at $252,000. Bridgeway Capital Management LLC purchased a new stake in shares of Tenax Therapeutics in the 4th quarter worth about $547,000. ADAR1 Capital Management LLC boosted its position in shares of Tenax Therapeutics by 19.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 63,673 shares of the specialty pharmaceutical company’s stock worth $776,000 after buying an additional 10,245 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Tenax Therapeutics in the 4th quarter valued at about $273,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.